Клинические исследования в Украине

Форум Пациентам

Исследования / № 01224808

Краткое названиеExtension Study of Biostate in Subjects With Von Willebrand Disease
Полное названиеAn Open-Label, Multi-Centre Extension Study to Assess the Efficacy and Safety of Biostate?® in Paediatric, Adolescent, and Adult Subjects With Von Willebrand Disease Who Completed Clinical Studies CSLCT-BIO-08-52 or CSLCTBIO-08-54
СпонсорCSL Behring
ИсточникCSL Behring
Под контролемBelarus: Ministry of Health
Bulgaria: Bulgarian Drug Agency
Germany: Paul-Ehrlich-Institut
Mexico: Ministry of Health
Poland: The Central Register of Clinical Trials
Russia: Ministry of Health and Social Development of the Russian Federation
Ukraine: State Pharmacological Center - Ministry of Health
Краткое описаниеThe aim of the Von Willebrand Disease (VWD) therapy is to treat and prevent bleeding
episodes due to abnormal platelet adhesion and abnormal blood coagulation as a result of low
or abnormal Von Willebrand Factor (VWF) and/or Factor VIII (FVIII) levels. The long-term
efficacy and safety of a VWF/FVIII concentrate, Biostate, will be investigated in children,
adolescents, and adults with VWD in whom treatment with a VWF product is required for
prophylactic therapy, haemostatic control during surgery, or control of a non-surgical,
spontaneous, or traumatic bleeding event.
СостояниеИдет набор
Дата началаOctober 2010
ФазаPhase 3
Вид исследованияAllocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
КритерииInclusion Criteria:

- Have completed Study CSLCT-BIO-08-52 (Assessment of Efficacy and Safety of Biostate
in Paediatric Subjects with Von Willebrand Disease) or Study CSLCT-BIO-08-54
(Assessment of Efficacy and Safety of Biostate in Adolescent or Adult Subjects with
Von Willebrand Disease).

- The subject and/or his/her legal guardian understand(s) the nature of the study and
has/have given written informed consent to participate in the study and is/are
willing to comply with the protocol.

Exclusion Criteria:

- Early discontinuation of a subject from the main studies CSLCT-BIO-08-52 or

- Mental condition rendering the subject (or the subject's legal guardian) unable to
understand the nature, scope and possible consequences of the study.

- Any condition that is likely to interfere with evaluation of the IMP or satisfactory
conduct of the study.

- Are not willing and/or not able to comply with the study requirements.

- Employee at the study site, or spouse/partner or relative of the Investigator or

- Female subjects of childbearing potential either not using, or not willing to use, a
medically reliable method of contraception for the entire duration of the study, or
not sexually abstinent for the entire duration of the study, or not surgically

- Intention to become pregnant during the course of the study.

- Pregnancy, or nursing mother.
Минимальный возрастN/A
Максимальный возрастN/A
УсловиеVon Willebrand Disease
Применяемое лечение
Контакты и расположение
Lviv Study Site
2011 © Клинические испытания в Украине